共 21 条
[1]
McKeage K., Lyseng-Williamson K.A., Trastuzumab: A pharmacoeconomic review of its use in early breast cancer, Pharmacoeconomics, 26, 8, pp. 699-719, (2008)
[2]
Plosker G.L., Keam S.J., Trastuzumab: A review of its use in the management of HER2-positive metastatic and early-stage breast cancer, Drugs, 66, 4, pp. 449-475, (2006)
[3]
Mass R.D., Press M.F., Anderson S., Et al., Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab, Clinical Breast Cancer, 6, 3, pp. 240-246, (2005)
[4]
Herceptin: Summary of product characteristics
[5]
Smith I., Procter M., Gelber R.D., Et al., 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial, Lancet, 369, 9555, pp. 29-36, (2007)
[6]
Romond E.H., Perez E.A., Bryant J., Et al., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 16, pp. 1673-1684, (2005)
[7]
Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Et al., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 16, pp. 1659-1672, (2005)
[8]
Suter T.M., Procter M., van Veldhuisen D.J., Et al., Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant Trial, J Clin Oncol, 25, 25, pp. 3859-3865, (2007)
[9]
Tan-Chiu E., Yothers G., Romond E., Et al., Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31, J Clin Oncol, 23, 31, pp. 7811-7819, (2005)
[10]
Perez E.A., Suman V.J., Davidson N.E., Et al., Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial, J Clin Oncol, 26, 8, pp. 1231-1238, (2008)